ViroMed said Thursday that it has published the bell-shaped drug dose response principle of VM202, a gene therapy, on the International Journal of Biochemistry and Biophysics (BBRC).

The company conducted the study to scientifically identify the bell-shaped drug dose response of VM202 observed in the U.S. phase 1 and 2 clinical trials for diabetic neuropathy (DPN).

In phase 1 clinical trial, Viromed administered 4 mg, 8 mg, and 16 mg of VM202 to diabetic neuropathy patients. As a result, the company confirmed that the analgesic effect at 8 mg was much better than 4 mg, while the 16 mg showed lower effects than 8 mg.

To confirm the data, the company administered 8 and 16 mg on each side of a patient’s leg during the phase 2 clinical trial and confirmed similar effects.

The medical community describes such data plot as bell-shaped.

In the Journal, Viromed researchers confirmed that the “bell-shaped” curves found in human clinical trials were also present in the cell culture systems. Also, the team identified molecular biochemical and biochemical principles of the drug.

In other words, when the concentration of hepatocyte growth factor (HGF) is low, the amount of c-met, which is HGF cell receptor, increases as the concentration increases. When it is too much, however, the concentration of the c-met receptor decreases.

“This study allowed us to understand the bell-shaped drug reaction principle of VM202,” Viromed CEO Kim Sun-young said. “This data shows that it is possible to create intellectual property in the field of drug delivery based on VM202 and HGF, and it will serve as a valuable basic data in the follow-up study.”

corea022@docdocdoc.co.kr

<© Korea Biomedical Review, All rights reserved.>